Fundamental Result Update

Dabur Q1FY22 Result Update



Dabur’ Q1FY22 results were significantly above our expectation owing to broad based performance across segments, particularly healthcare and Foods segments. Domestic business saw volume growth of 34.4%, was way above our estimate of 15.5%. The company did a 10% volume growth on 2 year CAGR, which is laudable given challenges amid covid related issue and supply chain disruption in rural area. International business reported CC growth of 34% YoY owing to broad – based performance across geographies. However Turkey business grew just 11.7% (Hobby brand was key disappointment).


Valuation & Outlook: Dabur management initiatives in the last 2 years in the form of: 1) aggressive product innovation launches, 2) continued expansion in the distribution in the urban and rural, 3) increase in advertisements spends owing to brand building exercise, creating image and business driven, 4) focus on the core business, 5) power brand strategy, 6) investment in technology & analytics, 7) improved go-to-market initiatives, and 8) cost savings efforts were ploughed back into the business for growth. We believe, this will keep Dabur way-ahead its competitor and will be able to report much stronger top-line and earnings growth, commensurate with the inherent potential of Herbal and Ayurveda ingredient through its Healthcare, F&B and HPC business. 

 


Tags: FundamentalResult Update


Search Reports

SEARCH

Reports

Daily Market Update...

Nifty opened higher but...

Read More

Daily Market Update...

Nifty opened higher, traded...

Read More

Daily Market Update...

Nifty opened higher, traded...

Read More

Daily Market Update...

Nifty opened higher but was...

Read More

Daily Market Update...

Nifty opened higher traded...

Read More

MM Q1 FY22 Result Update

M&M + MVML has reported...

Read More

IPCALLAB

SHORT TERM TRADING CALL: BUY...

Read More

GUJALKALI

SHORT TERM TRADING CALL: BUY...

Read More

SBI Q1FY22 Result Update

State Bank of India (SBI) has...

Read More

Indo Count Q1FY22 Result...

Indo Count Industries (ICIL)...

Read More

Subscribe to newsletter

Request a call back

DISCLAIMER: Investment in markets is subject to market risk, the views and investment tips expressed by our research entity on arihantcapital.com are product of their own. Whilst meticulous care has been taken to ensure that the facts stated are accurate and opinions given are fair and reasonable, neither the analyst nor any employee of our company is in any way is responsible for its contents and nor is its accuracy or completeness guaranteed. ArihantCapital.com offers the views and opinions for assistance only and these are not intended and must not be alone taken as the basis for an investment decision. We advise the users to check with certified experts before taking any investment decisions. The investments discussed in this material may not be suitable for all investors. The recipient alone shall be fully responsible/are liable for any decision taken on the basis of this material.